Differential Sex-Specific Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blocker Therapy on Arterial Function in Hypertension: CALIBREX Trial

被引:4
作者
Rogers, Steven C. [1 ]
Ko, Yi-An [1 ,4 ]
Quyyumi, Arshed A. [1 ]
Hajjar, Ihab [2 ,3 ]
机构
[1] Emory Clin Cardiovasc Res Inst, Dept Med, Div Cardiol, Atlanta, GA USA
[2] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Med, Div Gen Med & Geriatr, Atlanta, GA USA
[4] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA USA
关键词
blood pressure; population; pulse wave analysis; renin-angiotensin system; sex; PULSE-WAVE VELOCITY; EXPERT CONSENSUS DOCUMENT; LIPID-LOWERING TREATMENT; CORONARY-HEART-DISEASE; CARDIOVASCULAR EVENTS; AUGMENTATION INDEX; BLOOD-PRESSURE; RISK-FACTORS; ANTIHYPERTENSIVE DRUGS; MYOCARDIAL-INFARCTION;
D O I
10.1161/HYPERTENSIONAHA.122.19105
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Increased arterial stiffness is associated with adverse cardiovascular outcomes. We studied the sex-specific impact of angiotensin antagonists on vascular function in hypertension with the hypothesis that their effects on arterial stiffness may be variable in men and women. Methods: In 141 hypertensive participants with mild cognitive impairment (age 65.9 +/- 7.7, 57% female), candesartan (up to 32 mg, n=77) or lisinopril (up to 40 mg, n=64) were administered to achieve blood pressure <140/90 mm Hg. Pulse wave velocity, central pulse pressure, and central augmentation index were measured using applanation tonometry (SphygmoCor, Australia). Multivariate linear regression and mixed model analyses were performed using intention-to-treat and per protocol analyses for those completing the study. Results: Blood pressure reduction was similar among candesartan and lisinopril groups. Compared with candesartan, lisinopril therapy resulted in lower pulse wave velocity (0.5 +/- 0.8 versus -0.7 +/- 0.4 m/s, respectively; P=0.003) and central pulse pressure (-1 +/- 3 versus -7 +/- 4 mm Hg; P=0.03) after 1 year. There was a significant interaction by sex whereby the improvements in pulse wave velocity and central pulse pressure with lisinopril compared with candesartan were only observed in women. In contrast, there was greater improvement in augmentation index with candesartan compared with lisinopril (-4 +/- 7% versus -1.5 +/- 8%; P=0.05), with no sex differences. Conclusions: Despite equipotent antihypertensive effects, lisinopril was more effective than candesartan at lowering arterial stiffness in women. In contrast, candesartan was more effective than lisinopril in improving pulse wave reflections in both sexes. These findings demonstrate differential sex-specific effects of renin-angiotensin system antagonists on arterial function in hypertension that may contribute to long-term cardiovascular and neurocognitive outcomes in this population.
引用
收藏
页码:2316 / 2327
页数:12
相关论文
共 78 条
  • [1] Menopause and modifiable coronary heart disease risk factors: A population based study
    Agrinier, N.
    Cournot, M.
    Dallongeville, J.
    Arveiler, D.
    Ducimetiere, P.
    Ruidavets, J. -B.
    Ferrieres, J.
    [J]. MATURITAS, 2010, 65 (03) : 237 - 243
  • [2] Gender differences in large artery stiffness pre- and post puberty
    Ahimastos, AA
    Formosa, M
    Dart, AM
    Kingwell, BA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) : 5375 - 5380
  • [3] Al Khalaf MM, 2009, AM J CARDIOVASC DRUG, V9, P29, DOI 10.2165/00129784-200909010-00004
  • [4] Longitudinal Trajectories of Arterial Stiffness and the Role of Blood Pressure The Baltimore Longitudinal Study of Aging
    AlGhatrif, Majd
    Strait, James B.
    Morrell, Chris H.
    Canepa, Marco
    Wright, Jeanette
    Elango, Palchamy
    Scuteri, Angelo
    Najjar, Samer S.
    Ferrucci, Luigi
    Lakatta, Edward G.
    [J]. HYPERTENSION, 2013, 62 (05) : 934 - 941
  • [5] *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI [10.1001/jama, DOI 10.1001/JAMA.288.23.2981]
  • [6] Aronow WS, 2011, J AM SOC HYPERTENS, V5, P259, DOI [10.1016/j.jacc.2011.01.008, 10.1016/j.jash.2011.06.001]
  • [7] Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
    Black, HR
    Graff, A
    Shute, D
    Stoltz, R
    Ruff, D
    Levine, J
    Shi, Y
    Mallows, S
    [J]. JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (08) : 483 - 489
  • [8] Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease
    Bonetti, PO
    Barsness, GW
    Keelan, PC
    Schnell, TI
    Pumper, GM
    Kuvin, JT
    Schnall, RP
    Holmes, DR
    Higano, ST
    Lerman, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (10) : 1761 - 1768
  • [9] Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study
    Boutouyrie, Pierre
    Achouba, Assya
    Trunet, Patrick
    Laurent, Stephane
    [J]. HYPERTENSION, 2010, 55 (06) : 1314 - U54
  • [10] Bremner AD, 1997, CLIN EXP HYPERTENS, V19, P1263